First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

This study is ongoing, but not recruiting participants.

Sponsored by:	King Faisal Specialist Hospital & Research Center
Information provided by:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00537901

Purpose

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Condition	Intervention
Colonic Neoplasms Rectal Neoplasms	Radiation: First-Line Bevacizumab and Chemotherapy Drug: Bevacizumab

MedlinePlus related topics: Cancer

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Single Group Assignment

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Patients with metastatic cancer of colon or rectum

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00537901

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator:	Shouki Bazarbashi, MD	KFSH & RC
Principal Investigator:	Shouki Bazarbashi, MD	KFSH & RC

More Information

Study ID Numbers:	RAC #2041-082
Study First Received:	October 1, 2007
Last Updated:	October 1, 2007
ClinicalTrials.gov Identifier:	NCT00537901
Health Authority:	United States: Institutional Review Board

Keywords provided by King Faisal Specialist Hospital & Research Center:

Colon and Rectum Cancer

Study placed in the following topic categories:

Digestive System Neoplasms
Rectal Neoplasms
Gastrointestinal Diseases
Colonic Diseases
Bevacizumab
Intestinal Diseases
Rectal Diseases
Intestinal Neoplasms

Rectal neoplasm
Digestive System Diseases
Neoplasm Metastasis
Gastrointestinal Neoplasms
Colonic Neoplasms
Rectal cancer
Colorectal Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site
Antineoplastic Agents
Therapeutic Uses
Growth Substances

Physiological Effects of Drugs
Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009